+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2020

  • ID: 5146899
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 684 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 3SBio Inc
  • Astellas Pharma Inc
  • Evelo Biosciences Inc
  • Kine Sciences
  • Next Science Ltd
  • Seelos Therapeutics, Inc.
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2020, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews the key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 52, 25, 4, 65, 24 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 7 and 3 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3SBio Inc
  • Astellas Pharma Inc
  • Evelo Biosciences Inc
  • Kine Sciences
  • Next Science Ltd
  • Seelos Therapeutics, Inc.
  • MORE
Introduction
  • Atopic Dermatitis (Atopic Eczema) - Overview
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment

Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development

Atopic Dermatitis (Atopic Eczema) - Drug Profiles

Atopic Dermatitis (Atopic Eczema) - Dormant Projects
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products
  • Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by 3SBio Inc, H2 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, H2 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H2 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H2 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H2 2020
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • 3SBio Inc
  • Abate Med Inc
  • AbbVie Inc
  • Abeome Corp
  • Aclaris Therapeutics Inc
  • Adare Pharmaceuticals Inc
  • Akaal Pharma Pty Ltd
  • Akeso Inc
  • Alexion Pharmaceuticals Inc
  • Allergan Ltd
  • Amgen Inc
  • Amicogen Inc
  • Amorepacific Corp
  • Amytrx Therapeutics Inc
  • Annji Pharmaceutical Co Ltd
  • AOBiome LLC
  • Apimeds Inc
  • Arcutis Inc
  • Arena Pharmaceuticals Inc
  • Arrien Pharmaceuticals LLC
  • Asana BioSciences LLC
  • Aslan Pharmaceuticals Ltd
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atrapos Therapeutics LLC
  • Avixgen Inc
  • Azitra Inc
  • Bausch Health Companies Inc
  • Beijing Puqi Pharmaceutical Technology Co Ltd
  • Biomimetix JV LLC
  • Blueberry Therapeutics Ltd
  • Boehringer Ingelheim International GmbH
  • Botanix Pharmaceuticals Ltd
  • Calcico Therapeutics Ltd
  • Chugai Pharmaceutical Co Ltd
  • Clayton Biotechnologies Inc
  • Clevexel Pharma SAS
  • ConMed Biosciences Inc
  • CSA Biotechnologies LLC
  • Cutanea Life Sciences Inc
  • Daiichi Sankyo Co Ltd
  • Derm-Biome Pharmaceuticals Inc
  • Dermala Inc
  • Dermavant Sciences Inc
  • DermBiont Inc
  • Devonian Health Group Inc
  • DongKoo Bio & Pharma Co Ltd
  • DURECT Corp
  • EHL Bio Co Ltd
  • Eli Lilly and Co
  • Emerald Biotechnology Espana
  • Enzychem Lifesciences Corp
  • Evelo Biosciences Inc
  • Evotec SE
  • F. Hoffmann-La Roche Ltd
  • Forte Biosciences Inc
  • Galapagos NV
  • General Regeneratives Shanghai Ltd
  • GI Innovation Co Ltd
  • GL Pharm Tech Corp
  • Helix BioMedix Inc
  • Hill Dermaceuticals Inc
  • Hoth Therapeutics Inc
  • Huons Co Ltd
  • Ichnos Sciences Inc
  • Immune Pharmaceuticals Inc
  • Incyte Corp
  • Inflamalps SA
  • Innovation Pharmaceuticals Inc
  • Innovimmune Biotherapeutics Inc
  • Integral Molecular Inc
  • Japan Tobacco Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Johnson & Johnson
  • Jubilant Therapeutics Inc
  • JW Pharmaceutical Corp
  • Kine Sciences
  • Kiniksa Pharmaceuticals Ltd
  • KoBioLabs Inc
  • Krystal Biotech Inc
  • Kv1.3 Therapeutics
  • Kymab Ltd
  • Kymera Therapeutics LLC
  • Kyowa Kirin Co Ltd
  • Larix Bioscience LLC
  • Lead Pharma Holding BV
  • Leo Pharma AS
  • Liminal BioSciences Inc
  • Lipid Biologics LLC
  • Matrisys Bioscience Inc
  • MC2 Therapeutics AS
  • MD Healthcare Inc
  • Medicenna Therapeutics Corp
  • Micreos BV
  • Nektar Therapeutics
  • Nepsone ehf
  • Neuracle Science Co Ltd
  • Next Science Ltd
  • NovaCell Technology Inc
  • Novartis AG
  • Oasis Pharmaceuticals LLC
  • OliX Pharmaceuticals Inc
  • Ondek Pty Ltd
  • Oneness Biotech Co Ltd
  • Otsuka Holdings Co Ltd
  • Pantherics Inc
  • Pfizer Inc
  • Polyrizon Ltd
  • Provectus Biopharmaceuticals Inc
  • Pyramid Biosciences Inc
  • Qurient Co Ltd
  • Ralexar Therapeutics Inc
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Regeneus Ltd
  • Rhizen Pharmaceuticals SA
  • Ribomic Inc
  • SCM lifescience Co Ltd
  • Seelos Therapeutics, Inc.
  • Servatus Ltd
  • Shaperon Inc
  • Shulov Innovative Science Ltd
  • Sienna Biopharmaceuticals Inc
  • Signum Biosciences Inc
  • Signum Dermalogix Inc
  • Siolta Therapeutics Inc
  • siRNAgen Therapeutics Corp
  • Sosei Heptares
  • Sparrow Pharmaceuticals Inc
  • Spherium Biomed SL
  • StemRIM Inc
  • sterna biologicals Gmbh & Co KG
  • Sun Pharmaceutical Industries Ltd
  • Suzhou Connect Biopharmaceuticals Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • TaiwanJ Pharmaceuticals Co Ltd
  • Temisis Therapeutics
  • The Geneva Biotech Center SA
  • Therabest Co Ltd
  • Tianjin Hemay Pharmaceutical Co Ltd
  • Tolerys SA
  • Torrent Pharmaceuticals Ltd
  • Transdermal Therapeutic Technologies LLC
  • TWi Biotechnology Inc
  • UCB SA
  • Union Therapeutics AS
  • United Biomedical Inc
  • Vasomune Inc
  • Voronoi Group
  • Welichem Biotech Inc
  • Zhejiang I-Biological Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll